BCL2 and ovarian cancer: Taken together, these data show the simultaneous blocking of MDR1 and BCL2 genes, which are mediated by siRNA@PLGA NPs, enables to efficiently promote the sensitivity of drugs on MDR ovarian cancer cell lines.